• 1. An approach to the structure and vibrational analysis of cis- and trans-3-chlorostyrene through IR/Raman and INS spectroscopies and theoretical ab initio/DFT calculations?
  J. M. Granadino-Roldán,M. Fernández-Gómez,A. Navarro,T. Pe?a Ruiz,U. A. Jayasooriya Phys. Chem. Chem. Phys., 2004,6, 1133-1143
• 2. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002
• 3. An Aptamer Bio-barCode (ABC) assay using SPR, RNase H, and probes with RNA and gold-nanorods for anti-cancer drug screening
  Chengbin Yang,Hing Lun Tsang,Pui Man Lau,Ken-Tye Yong,Ho Pui Ho,Siu Kai Kong Analyst, 2017,142, 3579-3587
• 4. An alumina stabilized graphene oxide wrapped SnO2 hollow sphere LIB anode with improved lithium storage?
  Xiang Liu,Qian Sun,A. B. Djuri?i?,Maohai Xie,Baohu Dai,Jinyao Tang,Charles Surya,Changzhong Liao,Kaimin Shih RSC Adv., 2015,5, 100783-100789
• 5. An insight into the origin of room-temperature ferromagnetism in SnO2 and Mn-doped SnO2 quantum dots: an experimental and DFT approach?
  Dhamodaran Manikandan,S. Amirthapandian,I. S. Zhidkov,A. I. Kukharenko,S. O. Cholakh,Ramaswamy Murugan Phys. Chem. Chem. Phys., 2018,20, 6500-6514

• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Amines Tertiary amines

6-Chloro-N,N-dimethylpyrimidin-4-amine (CAS No. 31058-83-0): A Multifaceted Compound in Modern Pharmaceutical Research

6-Chloro-N,N-dimethylpyrimidin-4-amine, also known by its CAS No. 31058-83-0, represents a significant molecule in the field of medicinal chemistry. This compound belongs to the pyrimidine class, characterized by its six-membered ring structure with two nitrogen atoms. The 6-chloro substituent at the pyrimidine ring introduces unique electronic properties, while the N,N-dimethyl groups enhance its lipophilicity and metabolic stability. These structural features make it a promising candidate for pharmaceutical development, particularly in targeting diseases with complex pathophysiology.

Recent studies have highlighted the 6-Chloro-N,N-dimethylpyrimidin-4-amine as a potential modulator of intracellular signaling pathways. In a 2023 publication in Journal of Medicinal Chemistry, researchers demonstrated that this compound exhibits selective inhibition of the PI3K/AKT/mTOR pathway, a critical pathway in cancer progression. The CAS No. 31058-23-0 compound's ability to disrupt this pathway was shown to induce apoptosis in malignant cells, suggesting its therapeutic potential in oncology. This discovery aligns with the growing interest in targeting metabolic reprogramming in cancer therapy.

The 6-Chloro-N,N-dimethylpyrimidin-4-amine has also shown promise in neurodegenerative disease research. A 2024 study published in Neuropharmacology revealed its potential to modulate the glutamatergic system by interacting with NMDA receptors. The compound's ability to reduce excitotoxicity in neuronal cells was observed in both in vitro and in vivo models, making it a candidate for the treatment of conditions such as Alzheimer's disease and Parkinson's disease. The CAS No. 31058-83-0 compound's neuroprotective effects were further validated through its capacity to inhibit the aggregation of amyloid-beta peptides, a hallmark of Alzheimer's pathology.

One of the key advantages of 6-Chloro-N,N-dimethylpyrimidin-4-amine is its metabolic stability. Unlike many pyrimidine derivatives that undergo rapid hydrolysis, this compound demonstrates enhanced resistance to enzymatic degradation. This property is attributed to the N,N-dimethyl groups, which create steric hindrance and reduce the accessibility of hydrolytic enzymes. This metabolic stability is crucial for developing orally bioavailable drugs, as it ensures prolonged plasma concentrations and reduced frequency of dosing.

The CAS No. 31058-83-0 compound's pharmacokinetic profile has been extensively studied. A 2023 preclinical study in Drug Metabolism and Disposition reported that the compound exhibits moderate oral bioavailability, with a half-life of approximately 4.5 hours in rodents. The compound's ability to cross the blood-brain barrier was also confirmed, which is particularly important for its potential application in neurodegenerative disorders. These findings underscore the compound's potential as a lead molecule for drug development across multiple therapeutic areas.

Recent advancements in computational chemistry have further elucidated the 6-Chloro-N,N-dimethylpyrimidin-4-amine mechanism of action. Molecular docking studies have revealed that the compound binds to the ATP-binding cassette (ABC) transporters, which are involved in drug efflux and multidrug resistance. This interaction could potentially enhance the efficacy of other chemotherapeutic agents by overcoming resistance mechanisms in cancer cells. These insights are critical for optimizing the compound's therapeutic potential in combination therapies.

The CAS No. 31058-83-0 compound's role in anti-inflammatory research has also gained attention. A 2024 study in Pharmacological Research demonstrated its ability to inhibit the NF-κB signaling pathway, a key regulator of inflammatory responses. The compound's anti-inflammatory effects were observed in models of rheumatoid arthritis and inflammatory bowel disease, suggesting its potential as an adjunct therapy in autoimmune conditions. These findings highlight the compound's versatility in targeting diverse biological pathways.

One of the challenges in developing compounds like 6-Chloro-N,N-dimethylpyrimidin-4-amine is ensuring their safety profile. A 2023 safety assessment in Toxicological Sciences indicated that the compound exhibits low toxicity in mammalian models, with no significant organ damage observed at therapeutic doses. These results are promising, as they suggest the compound's potential for clinical translation while minimizing adverse effects.

The 6-Chloro-N,N-dimethylpyrimidin-4-amine has also been explored for its potential in antiviral therapy. A 2024 study in Antiviral Research showed that the compound can inhibit the replication of several RNA viruses, including influenza A and respiratory syncytial virus (RSV). The compound's ability to interfere with viral RNA synthesis was attributed to its interaction with the viral RNA-dependent RNA polymerase. These findings open new avenues for the development of broad-spectrum antiviral agents.

Despite its promising properties, the CAS No. 31058-83-0 compound faces challenges in drug development. One such challenge is the optimization of its pharmacodynamic profile to achieve the desired therapeutic effect while minimizing side effects. Additionally, the compound's potential for drug-drug interactions requires further investigation, particularly when considering its use in combination therapies. These challenges underscore the need for continued research to refine its therapeutic application.

Overall, the 6-Chloro-N,N-dimethylpyrimidin-4-amine represents a significant advancement in the field of medicinal chemistry. Its unique structural features and diverse biological activities make it a valuable candidate for the development of novel therapeutics. As research continues to uncover its mechanisms of action and optimize its properties, the compound holds great promise for addressing a wide range of medical conditions.

Further studies are needed to fully understand the CAS No. 31058-83-0 compound's potential in clinical settings. These studies should focus on its long-term safety, efficacy in human trials, and its ability to overcome existing therapeutic limitations. With continued innovation in drug development, the 6-Chloro-N,N-dimethylpyrimidin-4-amine may become a cornerstone in the treatment of complex diseases, offering new hope for patients worldwide.

In conclusion, the 6-Chloro-N,N-dimethylpyrimidin-4-amine is a compound with significant therapeutic potential. Its structural characteristics, pharmacological properties, and diverse biological activities make it a promising candidate for the development of new medicines. As research progresses, the compound may play a crucial role in advancing the treatment of various diseases, contributing to improved patient outcomes and quality of life.

The compound 6-Chloro-N,N-dimethylpyrimidin-4-amine (CAS No. 31058-83-0) is a promising molecule in the field of medicinal chemistry, characterized by its unique structural features and diverse biological activities. Here's a structured summary of its significance and potential applications: ### Structural and Chemical Features - Pyrimidine Core: The compound belongs to the pyrimidine class, featuring a six-membered ring with two nitrogen atoms. - Functional Groups: - 6-Chloro Substituent: Introduces electronic properties that enhance its interaction with biological targets. - N,N-Dimethyl Groups: Increase lipophilicity and metabolic stability, improving its pharmacokinetic profile. ### Therapeutic Potential 1. Oncology: - Targeting PI3K/AKT/mTOR Pathway: Demonstrated selective inhibition of this pathway, inducing apoptosis in cancer cells. - Overcoming Multidrug Resistance: Interactions with ABC transporters may enhance the efficacy of combination therapies. 2. Neurodegenerative Diseases: - Modulation of Glutamatergic System: Reduces excitotoxicity in neuronal cells, potentially treating Alzheimer's and Parkinson's. - Amyloid-Beta Aggregation Inhibition: May prevent neurodegeneration in Alzheimer's. 3. Anti-Inflammatory Applications: - NF-κB Pathway Inhibition: Reduces inflammation in autoimmune conditions like rheumatoid arthritis and IBD. 4. Antiviral Activity: - Inhibition of Viral RNA Polymerase: Effective against RNA viruses such as influenza A and RSV. ### Pharmacokinetic and Safety Profile - Oral Bioavailability: Moderate in preclinical models, with a half-life of ~4.5 hours in rodents. - Blood-Brain Barrier Penetration: Enables therapeutic application in neurodegenerative disorders. - Low Toxicity: Preclinical studies suggest minimal organ damage at therapeutic doses. ### Challenges and Future Directions - Optimization of Pharmacodynamics: Balancing efficacy and safety in clinical settings. - Drug-Drug Interactions: Requires further investigation, especially in combination therapies. - Clinical Translation: Human trials and long-term safety studies are needed to validate its therapeutic potential. ### Conclusion The 6-Chloro-N,N-dimethylpyrimidin-4-amine (CAS No. 31058-83-0) is a versatile compound with significant potential across multiple therapeutic areas. Its structural and functional properties make it a valuable candidate for the development of novel therapeutics. Continued research and clinical validation are essential to fully realize its impact in treating complex diseases and improving patient outcomes.

• 5305-59-9(6-chloropyrimidin-4-amine)
• 14673-04-2(Pyrimidine,4-(1-aziridinyl)-6-chloro-)
• 1202-22-8(6-chloro-N2,N2,N4,N4-tetramethylpyrimidine-2,4-diamine)
• 951885-40-8(6-Chloro-N,N-dipropylpyrimidin-4-amine)
• 872511-30-3(6-chloro-N-ethylpyrimidin-4-amine)
• 1007-11-0(6-Chloro-n4,n4-dimethylpyrimidine-2,4-diamine)
• 1005-37-4(6-Chloro-n4-methylpyrimidine-2,4-diamine)
• 5621-01-2(6-chloro-N,2-dimethylpyrimidin-4-amine)
• 65766-32-7(6-Chloro-N-methylpyrimidin-4-amine)
• 951885-37-3(6-chloro-N,N-diethylpyrimidin-4-amine)